PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector

OXFORD, England, June 30, 2015 /PRNewswire/ --

PharmaVentures is pleased to announce that it has acted as advisor to Chip-Man Technologies Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMTs world leading capabilities in cellular imaging and analysis.

This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures clients.

Fintan Walton, CEO, PharmaVentures, commented: "PharmaVentures is delighted to have delivered a successful and valuable outcome for our client in a sector where deal activity is buoyant."

Adrian Dawkes, VP, PharmaVentures, who was lead advisor added: "Cellular imaging and analysis technologies are increasingly important in areas such as regenerative medicine and stem cell technology. Japan is leading the way in many aspects of this research and Yokogawa is therefore an ideal home for CMTs technologies."

Over the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies world-wide.

About PharmaVentures, Ltd

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Their services include:

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

PharmaVentures is based in Oxford, UK, employs 20 professionals and has associates in North America, Europe, Latin America and Asia-Pacific.

FOR FURTHER INFORMATION, CONTACT:
 
Dr Fintan Walton
Chief Executive
PharmaVentures Ltd
+44-(0)1865-332700
enquiries@pharmaventures.com